Advertisements

Famodine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Famodine

Famodine is the commercial name for a medication containing the active ingredient Famotidine. It is widely used to manage conditions related to excessive stomach acid. The medicine is primarily known for its action as a targeted suppressant of acid secretion.

Property Description
Active ingredient Famotidine
Form Oral tablet, oral suspension, IV solution
Pharmacological class Histamine H2-receptor antagonist (H2-blocker)
Common use Relief of heartburn and acid indigestion
Origin Synthetic small molecule

What Type of Medicine is Famodine? (Identity and Pharmacological Class)

Famodine is a medicinal entity containing the synthetic active ingredient Famotidine, which is classified as an antisecretory agent belonging to the Histamine H2-receptor antagonist class, commonly known as an H2-blocker. Famotidine is a synthetic small molecule drug whose function is to suppress specific biological secretions. The categorization of Famotidine as an H2-blocker defines its precise mechanism: selectively preventing the body's natural histamine from stimulating the stomach cells responsible for triggering acid production. This specific drug class provides effective management of acid secretion.

Famotidine Forms and Composition

The active ingredient Famotidine is manufactured into several different pharmaceutical preparations for systemic use, including the standard oral tablet, chewable tablet, oral suspension (liquid), and intravenous (IV) solution. For oral preparations, Famotidine is combined with standard pharmaceutical excipients suitable for ingestion. Famotidine is utilized both as a single-ingredient product and, less commonly, as a component in a combination product, where it is paired with antacids like calcium carbonate and magnesium hydroxide to offer both rapid and sustained relief.

The General Purpose of H2-Blockers

The general purpose of Famodine is to create a less irritating environment in the upper digestive system by significantly reducing the volume and suppressing the concentration of gastric acid secreted by the stomach. This pharmacological action makes Famodine an effective means for the general alleviation of symptoms related to excessive acid production. The medicine's use is often illustrated in scenarios like providing relief from acute, post-meal heartburn or managing intermittent discomfort from acid indigestion.

Regulatory References

  1. Famotidine: MedlinePlus Drug Information
Advertisements

What side effects are possible with Famodine?

Possible Side Effects and Safety Information

Common Adverse Reactions

The most commonly reported side effects in clinical trials (occurring in 1% or more of patients) include headache, dizziness, constipation, and diarrhea.

Serious and Clinically Significant Adverse Reactions

Famodine is associated with several serious adverse reactions documented in regulatory labeling, involving multiple organ systems. These include Central Nervous System (CNS) adverse reactions such as confusion, hallucinations, delirium, agitation, and seizures. Cardiac safety concerns include QT prolongation and arrhythmias, particularly in patients with pre-existing heart conditions or severe kidney impairment.

Other serious events reported post-marketing include severe hypersensitivity reactions (e.g., anaphylaxis, angioedema), severe skin reactions (e.g., Stevens-Johnson syndrome/Toxic Epidermal Necrolysis), and blood dyscrasias (e.g., agranulocytosis, pancytopenia).

Safety Considerations for Specific Populations

  • Elderly Patients and those with moderate to severe renal impairment are at increased risk for the CNS adverse reactions and may require dosage adjustments due to slower drug clearance.
  • Prior to initiating treatment, the presence of a gastric malignancy must be evaluated, as Famodine may relieve symptoms without curing the condition.
  • Contraindications include a history of hypersensitivity to Famodine or other H2-receptor antagonists.
  • Avoid co-administration with tizanidine due to the potential for significantly increased tizanidine blood levels, which can lead to severe hypotension and excessive drowsiness.

Regulatory Summary

The official safety information outlines a profile where mild, common side effects exist alongside a risk of rare but serious systemic events, with elevated risk specifically identified for patients with impaired kidney function and the elderly. Dosage reduction is officially recommended in adults with moderate to severe renal impairment to manage the increased systemic exposure and mitigate the risk of adverse CNS and cardiac effects.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Famodine (Famotidine) is documented in regulatory sources to primarily affect the Central Nervous System (CNS) and the Cardiovascular System. Documented manifestations include confusion, delirium, hallucinations, agitation, drowsiness, and slurred speech. Cardiovascular signs may involve an abnormal heartbeat (rapid or slow) and low blood pressure (hypotension). Other physiological signs that may occur include vomiting, dizziness, and flushing.


Emergency Response and Mandatory Actions

Urgent medical help is required when specific severe outcomes are observed. Regulatory guidance mandates an immediate call to emergency services if the individual collapsed, had a seizure, has trouble breathing, or cannot be awakened. Additionally, contacting a Poison Control Center immediately is required in any suspected overdose case.

Overdose management is symptomatic and supportive, as no specific antidote is known. Supportive measures documented include administration of activated charcoal and continuous monitoring of vital signs, including ECG and blood pressure. Do NOT induce vomiting unless explicitly directed by a healthcare official.

A specific regulatory warning notes that elderly patients and individuals with renal impairment are at an increased risk for severe CNS adverse reactions due to the slower removal of Famodine from the body.

Advertisements

Therapeutic Uses of Famodine

What Famotidine treats: main uses and benefits

Famotidine is a medication used in situations involving certain distressing symptoms. Its therapeutic domain involves addressing conditions marked by temporary physiological imbalance, which contributes to easing the overall symptom load.

The medicine is commonly used for the symptomatic relief of heartburn, dyspepsia (indigestion), and acid reflux. Famotidine is also relevant for managing conditions characterized by periods of heightened symptoms. It is used for managing active duodenal and benign gastric ulcers, which are symptoms related to inflammatory or irritative states. Additionally, it is considered relevant for easing symptoms linked to Gastroesophageal Reflux Disease (GERD), including conditions where functional stability becomes affected by oesophageal erosion. It is also applied in conditions marked by increased physiological stress, such as Zollinger-Ellison syndrome. This use supports the patient during difficult episodes by easing distress.

One patient-oriented benefit is:

"...provides supportive relief when symptoms interfere with routine activities."

This supportive relief may assist with maintaining day-to-day comfort during symptomatic periods.

Quick Fact: Relief for symptoms related to physical discomfort.

Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Information

Official regulatory documents define specific populations who can and cannot use Famodine (Famotidine).

Absolute Contraindications

Famodine is contraindicated and must not be used by individuals with a confirmed history of serious hypersensitivity reactions (allergy) to Famotidine or to any other medicine in the Histamine H2-receptor antagonist class. For patients being treated for gastric ulcers, the possibility of an underlying gastric malignancy must be excluded prior to initiating therapy.

Population and Condition-Based Restrictions

Population/Condition Regulatory Status
Renal Impairment (Moderate to Severe) Conditional Use required; a mandatory dosage reduction is necessary to prevent drug accumulation and the risk of CNS adverse reactions.
Pregnancy Not Recommended unless the potential benefit is determined to outweigh the risk.
Lactation (Breastfeeding) The mother is generally advised to stop taking Famodine or stop breastfeeding due to drug excretion in breast milk.
Pediatric Use (OTC Heartburn) Not established for children under 12 years of age.
Older Adults (Geriatric) Eligible, but caution is advised due to increased risk of CNS effects, especially with concurrent decreased kidney function.

These restrictions, including age limits and conditions, are established by government regulatory bodies to ensure appropriate use.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Famodine (Famotidine) has officially documented interaction patterns primarily concerning drug exposure and administration timing, as specified in regulatory information.

Pharmacokinetic and Exposure Interactions

Famodine's action in reducing gastric acidity can lead to a significant reduction in systemic exposure and potential loss of efficacy for co-administered medicines that depend on an acidic stomach environment for their absorption. Examples of such medicines include certain antifungals and specific kinase inhibitors.

Co-administration with Probenecid is known to increase Famodine's plasma concentrations due to the inhibition of its renal tubular secretion, which can elevate exposure by up to 50%.

Strong restrictions apply to the combination with Tizanidine, a CYP1A2 substrate, due to the potential for substantial increases in Tizanidine blood levels, and its concomitant use should be avoided.

Administration Timing and Special Populations

Specific administration timing rules are required for certain co-administered products. To prevent reduced absorption of Famodine, Antacids should be separated, with Famodine administered 1 to 2 hours beforehand. Similarly, Sucralfate should not be administered within 2 hours of a Famodine dose.

Regarding substances, regulatory studies have shown that co-administration with alcohol does not augment expected blood alcohol levels.

Interaction risk is heightened in specific patient groups; individuals with moderate to severe renal impairment and elderly patients are at an increased risk of elevated Famodine exposure due to reduced clearance.

Advertisements

Mechanism of Action

H2 Receptor Antagonism: Molecular Blockade

Famodine acts as a competitive antagonist, engaging the mathbfH2 receptors located on the surface of the gastric parietal cells. By occupying the receptor site, Famodine prevents the natural signaling molecule, histamine, from binding and initiating the acid secretion process. This direct receptor interference reduces the initiation signal for the gastric acid secretion pathway.


Pathway Modulation and Acid Output

The drug modifies activity within the secretory pathway by disrupting the intracellular cascade that normally leads to increased cyclic AMP (cAMP) levels. Interruption of this signaling sequence reduces the capacity of the parietal cell to mobilize and activate the H^+/ K^+-ATPase (proton pump). This mechanism results in a sustained reduction of the acid-secretion signal intensity.


Alteration of Luminal Acidity

The mechanistic cascade ultimately leads to a system-level physiological adjustment: the reduced output of hydrochloric acid into the stomach lumen. This action diminishes the concentration of free hydrogen ions, resulting in a predictable shift toward a higher pH and modification of the local chemical environment within the upper digestive tract.

Advertisements

Dosage and Administration Information

How to Use Famodine

The administration of Famodine (Famotidine) is governed by specific instructions outlined in official labeling to ensure standardized use. The medicine is primarily administered via the oral route as tablets or an oral suspension, which may be taken with or without food. The intravenous (IV) solution is reserved for short-term use in hospital settings when oral intake is not feasible.

Official Dosing and Frequency Patterns

The usage pattern depends on the intended duration of treatment, with standard regimens defining the frequency and dose over time.

Usage Pattern Standard Adult Regimen Frequency and Duration
Active Conditions 20 mg or 40 mg Once daily (at bedtime) or Twice daily (e.g., up to 8 weeks)
Maintenance Therapy 20 mg Once daily (at bedtime) (e.g., up to 1 year)

Administration and Procedural Conditions

Official instructions stipulate that the oral suspension must be shaken vigorously prior to use, and tablets are generally swallowed whole. When used over the counter for prevention, the dose should be administered 10 to 60 minutes before consuming triggering foods or beverages.

For specific populations, dose adjustments are procedurally required. Patients with renal impairment (reduced kidney function) typically require a reduction in the total dose or an extension of the dosing interval to approximately 36 to 48 hours to align with the body’s clearance rate. There are no adjustments required for older adults based on age alone.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Investigational Compound for Joint Health

Famodine, as a single agent, has been primarily studied for conditions related to stomach acid reduction. Research has explored whether joint mobility is associated with the compound and examined the compound's relationship to pain reports when used in combination with other anti-inflammatory drugs. Studies evaluated whether the compound modulates inflammatory pathways, with research exploring its possible association with joint discomfort.

Published Clinical Trials

Primary Outcome: Mobility and Discomfort

  • Randomized controlled trials (RCTs) investigating Famodine in fixed-dose combination with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have focused on the combination's use in conditions like osteoarthritis and rheumatoid arthritis. These trials primarily evaluated the efficacy of the NSAID component on pain and mobility.
  • Specifically, pooled efficacy and safety analyses of two large-scale RCTs reported that the combination was associated with fewer endoscopically documented upper gastrointestinal ulcers compared with the NSAID alone.

Secondary Outcome: Safety and Tolerability

  • The compound's tolerability during long-term use in combination trials has been studied. The most commonly reported adverse events were gastrointestinal issues.
  • Trials involving people with severe liver disease were limited, and data from animal models suggested further investigation into hepatic parameters may be useful.

Pre-clinical Data

Pre-clinical (in vitro and animal) studies suggested that the compound may interact with specific molecular targets involved in cartilage integrity or reduce inflammatory cytokines, though these findings were not from clinical trials focused on joint disease. A comprehensive mechanism of action for this investigational compound remains to be defined through further human clinical trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Famodine (FAQ)

Q: Is Famodine used for conditions other than heartburn and ulcers?

A: Yes, official regulatory documents indicate that Famodine is approved for treating several conditions beyond general heartburn and ulcers. These conditions include symptomatic relief for gastroesophageal reflux disease (GERD) and management of conditions where the body produces excessive acid, such as Zollinger-Ellison syndrome.


Q: Is Famodine meant for immediate heartburn relief or longer-term treatment?

A: Famodine is defined for both short-term and long-term use. The onset of its acid-reducing effect occurs within one hour of taking an oral dose, reflecting its role in managing acute symptoms. The medicine also has established regulatory guidelines for long-term use, including management of active conditions and maintenance.


Q: What is the difference between prescription Famodine and the over-the-counter version?

A: The primary difference lies in the dosage strength and intended use. Prescription versions contain higher doses for treating conditions like ulcers or GERD, according to regulatory labels. Over-the-counter versions are generally lower dose and are approved for the self-treatment and prevention of common heartburn.


Q: How does the action of Famodine compare to a Proton Pump Inhibitor (PPI) like Omeprazole?

A: Famodine and PPIs affect acid production at different stages. Famodine is a histamine H2-receptor antagonist, meaning it blocks a triggering signal that tells stomach cells to make acid. PPIs, conversely, block the final step of acid secretion by inhibiting the proton pump inside the cell.


Q: Why does Famodine seem to work faster than some other acid-reducing medicines?

A: According to pharmacodynamic studies, the anti-secretory effect of Famodine begins within one hour after a patient takes the oral dose. This timing is a result of its mechanism as an H2-receptor antagonist, which directly blocks a signal for acid release.


Q: Does Famodine treat the cause of acid problems or just the symptoms?

A: Famodine is classified as an antisecretory agent because its mechanism involves reducing the amount of acid the stomach produces. By controlling acid levels, the medicine is used to alleviate the symptoms associated with excessive acid.


Q: What is the typical duration of effect for a standard dose of Famodine?

A: Official pharmacodynamic information indicates that the inhibition of acid secretion from a standard dose typically lasts for 10 to 12 hours. This information helps describe the drug's sustained effect in the body.


Q: If I take Famodine at night, how long does the acid control last through the night?

A: Studies indicate that single evening doses have been shown to inhibit nocturnal acid secretion for a period of at least 10 hours. This action is consistent with its use to manage acid production during the nocturnal period.


Q: Do side effects of Famodine typically go away after stopping the medicine?

A: Official documents describe that psychological disturbances, which are rare Central Nervous System (CNS) effects, have been reported as reversible upon cessation of treatment. This observation primarily relates to reports on these specific reactions.


Q: Does Famodine have a potential to cause hair loss, as some people claim online?

A: Official safety information lists alopecia (hair loss) as a very rare adverse effect that has been reported in post-marketing experience or clinical trials.


Q: Can taking Famodine cause stomach pain or nausea initially?

A: Official safety information lists certain gastrointestinal issues as uncommon side effects. These may include nausea, vomiting, or generalized abdominal discomfort or distension.


Q: Does Famodine interact with common over-the-counter pain relievers like Ibuprofen or Aspirin?

A: Official product information indicates that Famodine may alter the plasma concentrations of certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common OTC pain relievers. However, this change is often described as being of limited clinical significance.


Q: Is it true that Famodine can affect the blood thinning medicine Warfarin?

A: Regulatory documents for Famodine typically state that no clinically significant interactions with Warfarin have been identified. However, some regulatory documents note that it has been reported to potentially increase the effect of Warfarin, which is associated with an increased risk of bleeding.


Q: Are there any common foods or drinks that might interact with or reduce the effectiveness of Famodine?

A: Regulatory information indicates that Famodine's bioavailability may be slightly increased by food. This slight change in absorption is not generally considered to be clinically significant.


Q: What information is available regarding Famodine use in people with pre-existing liver conditions?

A: Rare instances of liver-related adverse reactions have been reported in official safety documents. These reports have included hepatitis, cholestatic jaundice, and rare cases of worsening of existing hepatic (liver) disease.


Q: Why do some official drug documents recommend taking Famodine at bedtime?

A: Famodine is often recommended for dosing at bedtime because studies show it is highly effective at inhibiting nocturnal acid secretion. This action is consistent with its prescribed role in managing acid production during the nocturnal period.


Q: Are there any known long-term effects of taking Famodine daily for many years?

A: Official safety information indicates that the risk of certain serious effects, such as a prolonged QT interval (a cardiac risk) and Central Nervous System (CNS) effects, may be increased with long-term Famodine use. This elevated risk is specifically noted for patients who have existing risk factors like impaired kidney function.


Q: What is the typical timeframe for seeing an improvement in ulcer symptoms when taking Famodine?

A: Studies have examined the time to achieve relief of ulcer symptoms, with results indicating that the time to complete relief of daytime and nighttime pain was shorter for patients receiving Famodine compared to placebo.


Q: Is Famodine available as a generic medicine?

A: Yes, the active ingredient, Famotidine, which is the non-proprietary name, is officially available as a generic medicine.

Advertisements

How should Famodine be stored and disposed of?

How to Store and Dispose of Famodine

Famotidine must be stored under Controlled Room Temperature (typically 20 C to 25 C or 68 F to 77 F). The product must be protected from moisture and light and should be kept in its tightly closed original container.

Form-Specific Stability and Disposal

The reconstituted oral suspension has a limited shelf life and must be discarded after 30 days; this liquid preparation and the injection solution must not be frozen. All forms must be stored out of the sight and reach of children.

Unused or expired Famotidine must be disposed of in accordance with local regulatory requirements, and a healthcare professional should be consulted for proper disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Famodine found in:

A-Z Index: